Breast Cancer Experts Suggest Minimum Benefit For New pCR Surrogate
Executive Summary
Pathologic complete response in neoadjuvant breast cancer trials is reasonably likely to result in better long-term outcomes, but how big the pCR improvement needs to be is a matter of guesswork.